Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Page 1
Prediction of outcomes after second-line treatment for acute graft-versus-host disease.
Vo P, Gooley TA, Carpenter PA, Sorror ML, MacMillan ML, DeFor TE, Martin PJ. Vo P, et al. Among authors: sorror ml. Blood Adv. 2022 Jun 14;6(11):3220-3229. doi: 10.1182/bloodadvances.2021006220. Blood Adv. 2022. PMID: 35235948 Free PMC article.
Acute graft-versus-host disease (GVHD) requiring second-line treatment represents a highly morbid complication of allogenic hematopoietic cell transplantation (HCT). Recent studies have defined short-term outcomes after second-line treatment for acute GVHD, but longer-t …
Acute graft-versus-host disease (GVHD) requiring second-line treatment represents a highly morbid complication of allogenic hematopoietic ce …
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
Yeh AC, O'Donnell PV, Schoch G, Martin PJ, McFarland C, McCune JS, Cooper JP, Doney K, Flowers MED, Sorror ML, Appelbaum FR, Storer BE, Gooley T, Deeg HJ. Yeh AC, et al. Among authors: sorror ml. Bone Marrow Transplant. 2022 Feb;57(2):198-206. doi: 10.1038/s41409-021-01518-0. Epub 2021 Nov 5. Bone Marrow Transplant. 2022. PMID: 34741096 Free PMC article.
We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n = 23] or 250 [n = 17] mg/m(2)) and thymoglobulin (THY). ...THY is effectiv …
We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning w …
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Cordeiro A, et al. Among authors: sorror ml. Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13. Biol Blood Marrow Transplant. 2020. PMID: 31419568 Free PMC article. Clinical Trial.
Most of the late events observed in this cohort were not severe, and many could be related to previous or subsequent therapies, suggesting a safe long-term profile of CD19-targeted CAR-T cell immunotherapy....
Most of the late events observed in this cohort were not severe, and many could be related to previous or subsequent therapies, suggesting a …
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.
Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ. Woo J, et al. Among authors: sorror ml. Haematologica. 2020 Mar;105(3):652-660. doi: 10.3324/haematol.2019.218677. Epub 2019 Jul 9. Haematologica. 2020. PMID: 31289199 Free PMC article.
Chronic myelomonocytic leukemia (CMML) is a heterogeneous group of clonal hematopoietic malignancies with variable clinical and molecular features. We analyzed long-term results of allogeneic hematopoietic cell transplantation in patients with CMML and determined clinical …
Chronic myelomonocytic leukemia (CMML) is a heterogeneous group of clonal hematopoietic malignancies with variable clinical and molecular fe …
Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Elsawy M, Sorror ML. Elsawy M, et al. Among authors: sorror ml. Bone Marrow Transplant. 2016 Oct;51(10):1283-1300. doi: 10.1038/bmt.2016.141. Epub 2016 Jun 6. Bone Marrow Transplant. 2016. PMID: 27272454 Review.
Performance status scales and comprehensive geriatric assessment tools might uncover additional overall health limitations that affect long-term survival among older recipients of allogeneic HCT. Other models include the pretransplantation assessment of mortality score tha …
Performance status scales and comprehensive geriatric assessment tools might uncover additional overall health limitations that affect long- …
Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD, Alan Potts D Jr, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM. Cassaday RD, et al. Among authors: sorror ml. Leuk Lymphoma. 2016 Sep;57(9):2109-18. doi: 10.3109/10428194.2016.1160080. Epub 2016 Mar 22. Leuk Lymphoma. 2016. PMID: 27002921 Free PMC article.
In conclusion, adults with ALL in MRD(Neg) CR1 following adult-inspired therapy had similar OS with or without HCT, and HCT in MRD(Neg) CR2 + can yield long-term survival....
In conclusion, adults with ALL in MRD(Neg) CR1 following adult-inspired therapy had similar OS with or without HCT, and HCT in MRD(Neg) CR2 …
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG. Vaughn JE, et al. Among authors: sorror ml. Cancer. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498. Epub 2015 Jul 24. Cancer. 2015. PMID: 26207349 Free PMC article.
CONCLUSIONS: Nonmyeloablative allogeneic HCT provides a long-term survival benefit for patients with relapsed MCL, including those with refractory disease or multiple relapses....
CONCLUSIONS: Nonmyeloablative allogeneic HCT provides a long-term survival benefit for patients with relapsed MCL, including those wi …
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ, Rezvani AR, Storb RF, Press OW, Gopal AK. Cassaday RD, et al. Among authors: sorror ml. Biol Blood Marrow Transplant. 2015 Feb;21(2):281-7. doi: 10.1016/j.bbmt.2014.10.024. Epub 2014 Nov 1. Biol Blood Marrow Transplant. 2015. PMID: 25445025 Free PMC article. Clinical Trial.
However, for the many patients unable to achieve this state, outcomes are poorly described and methods to improve results are unknown. We sought to describe the long-term follow-up and predictive factors for these poor-risk patients unable to achieve CR before NMAT. ...
However, for the many patients unable to achieve this state, outcomes are poorly described and methods to improve results are unknown. We so …
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML. Duncan CN, et al. Among authors: sorror ml. Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006. Epub 2014 Oct 12. Biol Blood Marrow Transplant. 2015. PMID: 25316109 Free PMC article.
Among patients with acute leukemia and myelodysplastic syndromes who receive a second allogeneic HCT for relapse and survive disease free for at least 1 year, many can be expected to survive long term. However, they continue to be at risk for relapse and nonrelapse morbidi …
Among patients with acute leukemia and myelodysplastic syndromes who receive a second allogeneic HCT for relapse and survive disease free fo …
Clinical guide to fertility preservation in hematopoietic cell transplant recipients.
Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY, Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, Stratton P, Sorror ML, Warwick AB, Wingard JR, Loren AW, Majhail NS. Joshi S, et al. Among authors: sorror ml. Bone Marrow Transplant. 2014 Apr;49(4):477-84. doi: 10.1038/bmt.2013.211. Epub 2014 Jan 13. Bone Marrow Transplant. 2014. PMID: 24419521 Free PMC article. Review.
With broadening indications, more options for hematopoietic cell transplantation (HCT) and improvement in survival, the number of long-term HCT survivors is expected to increase steadily. Infertility is a frequent problem that long-term HCT survivors and their partn …
With broadening indications, more options for hematopoietic cell transplantation (HCT) and improvement in survival, the number of long-te …
20 results